Last reviewed · How we verify

Ondansetron oral tablets

GlaxoSmithKline · Phase 3 active Small molecule

Ondansetron oral tablets is a Serotonin 5-HT3 receptor antagonist Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy. Also known as: Dexamethasone intravenous, Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous.

Ondansetron works by blocking serotonin receptors in the body, which helps to reduce nausea and vomiting.

Ondansetron works by blocking serotonin receptors in the body, which helps to reduce nausea and vomiting. Used for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy.

At a glance

Generic nameOndansetron oral tablets
Also known asDexamethasone intravenous, Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous
SponsorGlaxoSmithKline
Drug classSerotonin 5-HT3 receptor antagonist
Target5-HT3 receptor
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

This is achieved through the antagonism of 5-HT3 receptors in the central nervous system and the gastrointestinal tract. By blocking these receptors, ondansetron reduces the vomiting reflex and alleviates nausea.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ondansetron oral tablets

What is Ondansetron oral tablets?

Ondansetron oral tablets is a Serotonin 5-HT3 receptor antagonist drug developed by GlaxoSmithKline, indicated for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy.

How does Ondansetron oral tablets work?

Ondansetron works by blocking serotonin receptors in the body, which helps to reduce nausea and vomiting.

What is Ondansetron oral tablets used for?

Ondansetron oral tablets is indicated for Prevention of nausea and vomiting caused by cancer chemotherapy, Prevention of nausea and vomiting caused by radiation therapy.

Who makes Ondansetron oral tablets?

Ondansetron oral tablets is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Ondansetron oral tablets also known as anything else?

Ondansetron oral tablets is also known as Dexamethasone intravenous, Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous.

What drug class is Ondansetron oral tablets in?

Ondansetron oral tablets belongs to the Serotonin 5-HT3 receptor antagonist class. See all Serotonin 5-HT3 receptor antagonist drugs at /class/serotonin-5-ht3-receptor-antagonist.

What development phase is Ondansetron oral tablets in?

Ondansetron oral tablets is in Phase 3.

What are the side effects of Ondansetron oral tablets?

Common side effects of Ondansetron oral tablets include Headache, Dizziness, Constipation, Diarrhea, Fatigue.

What does Ondansetron oral tablets target?

Ondansetron oral tablets targets 5-HT3 receptor and is a Serotonin 5-HT3 receptor antagonist.

Related